The FDA Needs a MAGA Style Reboot

 Julio Rivera argues that the FDA requires significant reforms, particularly due to the past leadership of Dr. Vinay Prasad, whose tenure is viewed as harmful to the agency’s mission. Rivera emphasizes the importance of changing not only personnel but also the underlying policies that conflict with the Trump administration’s goals.

1. Prasad's Departure: Dr. Vinay Prasad, who briefly led the FDA’s Center for Biologics Evaluation and Research, is no longer at the FDA. His exit is portrayed as a result of personal reasons, but Rivera believes it was due to incompetence and ideology that conflicted with Trump's healthcare agenda.

2. Criticism of Leadership: FDA Commissioner Marty Makary is criticized for hiring Prasad in the first place and is accused of wanting to bring him back. Rivera asserts that Makary’s support for Prasad indicates deeper issues within the FDA’s leadership.

3. Impact of Prasad’s Policies: Under Prasad, the FDA increased rejections of drug applications, often for non-safety-related reasons, which Rivera claims slows down critical treatments for patients. This contrasts sharply with the need for faster approvals to support innovation and patient access.

4. Regulatory Culture: Rivera highlights a shift from a "Right to Try" approach, which promotes patient access to innovative treatments, to a "Right to Wait" mentality, characterized by unnecessary red tape and regulatory delays.

5. Continuing Challenges at the FDA: Even though Prasad is no longer present, the challenges he left behind persist. Rivera argues that as long as Makary remains, the progressive influence at the FDA will continue, stifling the agency’s effectiveness.

6. Call for Leadership Change: Rivera insists that for true reform to occur, not only should Prasad be removed but Makary must also be replaced. He argues that only then can the FDA align with the administration’s patient-first policies and dismantle the bureaucratic barriers that hinder innovation.

7. Broader Implications: The piece stresses that personnel decisions directly affect policy outcomes. Rivera argues that the FDA must be rebuilt to prioritize patients over bureaucratic interests, which aligns with Trump's commitments during his campaign.

The article emphasizes the urgent need for a restructure at the FDA, urging for a complete overhaul in leadership and approach. Rivera's focus is on ensuring that past mistakes are not repeated, particularly by avoiding reappointments of individuals like Prasad and ensuring adherence to a government focused on patient care. For the Trump administration to succeed in healthcare reform, a staunch dismissal of previous failures and a commitment to new, aligned leadership is essential. 

https://www.americanthinker.com/articles/2025/08/the_fda_needs_a_maga_style_reboot.html